Key Points
- CEO Thomas Chen purchased 12,757 Neonc Technologies shares at an average price of $5.49, investing approximately $70,036 and increasing his direct ownership by 1,345.68% to 13,705 shares.
- Neonc reported a quarterly loss of $0.58 per share, missing the analyst consensus estimate of a $0.12 loss by $0.46. The stock opened at $4.56, versus a 52-week range of $3.01 to $12.99.
- Analyst views are mixed: three analysts rate the stock Buy, one Hold and one Sell, producing a consensus Hold rating and a $16 average price target; several institutions also recently established or expanded positions.
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) CEO Thomas Chen purchased 12,757 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average cost of $5.49 per share, for a total transaction of $70,035.93. Following the completion of the acquisition, the chief executive officer directly owned 13,705 shares of the company's stock, valued at $75,240.45. This represents a 1,345.68% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Neonc Technologies Stock Performance
Shares of NTHI stock opened at $4.56 on Friday. The stock's fifty day moving average is $4.14 and its two-hundred day moving average is $5.95. Neonc Technologies Holdings, Inc. has a fifty-two week low of $3.01 and a fifty-two week high of $12.99.
Neonc Technologies (NASDAQ:NTHI - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.46).
Analysts Set New Price Targets
A number of analysts have recently issued reports on NTHI shares. Weiss Ratings downgraded shares of Neonc Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, June 24th. Alliance Global Partners assumed coverage on Neonc Technologies in a research note on Tuesday, May 19th. They set a "buy" rating and a $13.00 target price on the stock. BTIG Research reissued a "buy" rating and set a $15.00 target price on shares of Neonc Technologies in a research note on Tuesday, May 26th. Wall Street Zen lowered shares of Neonc Technologies from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Finally, Maxim Group started coverage on Neonc Technologies in a research report on Monday, May 18th. They set a "buy" rating and a $20.00 price objective for the company. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Neonc Technologies has an average rating of "Hold" and a consensus target price of $16.00.
Get Our Latest Stock Analysis on Neonc Technologies
Institutional Trading of Neonc Technologies
Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE acquired a new position in shares of Neonc Technologies during the 2nd quarter worth $1,017,000. BlackRock Inc. purchased a new stake in shares of Neonc Technologies in the second quarter valued at $815,000. Global Retirement Partners LLC purchased a new position in Neonc Technologies during the second quarter worth about $126,000. Westmount Partners LLC grew its holdings in Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company's stock valued at $893,000 after buying an additional 153,858 shares during the period. Finally, 683 Capital Management LLC purchased a new stake in shares of Neonc Technologies during the 4th quarter valued at $442,000.
Neonc Technologies Company Profile
(
Get Free Report)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
